Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-04-26
2011-04-26
Coleman, Brenda L (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C540S557000
Reexamination Certificate
active
07932249
ABSTRACT:
The present invention relates olanzapine pamoate dihydrate, pharmaceutical compositions thereof and use in treating certain mental disorders, such as schizophrenia.
REFERENCES:
patent: 3354036 (1967-11-01), Jelinek
patent: 3676557 (1972-07-01), Lachman et al.
patent: 3904670 (1975-09-01), Ricard et al.
patent: 3956330 (1976-05-01), Corey, Jr. et al.
patent: 4016273 (1977-04-01), Sieger et al.
patent: 4076942 (1978-02-01), Smith et al.
patent: 4320124 (1982-03-01), Koe
patent: 4594357 (1986-06-01), Dell et al.
patent: 4675189 (1987-06-01), Kent et al.
patent: 4906474 (1990-03-01), Langer et al.
patent: 4977150 (1990-12-01), Chakrabarti
patent: 5229382 (1993-07-01), Chakrabarti et al.
patent: 5292760 (1994-03-01), Martin et al.
patent: 5439688 (1995-08-01), Orsolini et al.
patent: 5605897 (1997-02-01), Beasley, Jr. et al.
patent: 5612346 (1997-03-01), Mesens et al.
patent: 5639480 (1997-06-01), Bodmer et al.
patent: 5643604 (1997-07-01), Uribe et al.
patent: 5693336 (1997-12-01), Moynihan
patent: 5723467 (1998-03-01), Mesens et al.
patent: 5736152 (1998-04-01), Dunn
patent: 5736541 (1998-04-01), Bunnell et al.
patent: 5773032 (1998-06-01), Engel et al.
patent: 5776885 (1998-07-01), Orsolini et al.
patent: 5776928 (1998-07-01), Beasley, Jr.
patent: 6169084 (2001-01-01), Bunnell et al.
patent: 6617321 (2003-09-01), Allen et al.
patent: 7303764 (2007-12-01), Allen et al.
patent: 0214501 (1987-03-01), None
patent: 0487674 (1992-06-01), None
patent: 0215313 (1992-07-01), None
patent: 0569096 (1993-11-01), None
patent: 0454436 (1995-09-01), None
patent: 1343936 (1974-01-01), None
patent: 1539277 (1979-01-01), None
patent: 1284333 (1988-05-01), None
patent: 7196510 (1993-12-01), None
patent: 9157159 (1995-12-01), None
patent: 94/10982 (1994-05-01), None
patent: 96/15815 (1996-05-01), None
patent: 96/29995 (1996-10-01), None
patent: 96/30374 (1996-10-01), None
patent: 96/30375 (1996-10-01), None
patent: 96/32948 (1996-10-01), None
patent: 96/38151 (1996-12-01), None
patent: 96/38152 (1996-12-01), None
patent: 97/09985 (1997-03-01), None
patent: 98/11893 (1998-03-01), None
patent: WO-03/037903 (2003-05-01), None
patent: 2006/073886 (2006-07-01), None
Berge et al., “Pharmaceutical Salts”, J. Pharm. Sci., vol. 66, No. 1, pp. 1-19 (Jan. 1977).
Van Der Sluis et al., “Solvents and X-Ray Crystallography”, J. Of Crystal Growth 97, pp. 645-656 (1989).
Caldwell et al., “Latentiation of dihydrostreptomycin by pamoate dormation”, J. Pharm. Sci., pp. 1689-1690 (Jun. 1970).
Citrome, “Olanzapine pamoate: a stick in time? A review of the efficacy and safety profile of new depot formulation of a second-generation antipsychotic”, Int. Journal of Clinical Practice, vol. 63 (1), 140-150, (Jan. 2009).
Coatney et al., “Further observation on the antimalarial activity of CI-501 (Camoloar) against the chesson strain of vivax malaria”, Laboratory of Parasite Chemotherapy, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, pp. 383-385, 1964.
Coleman et al., Biopharmaceutics & Drug Disposition, vol. 7, pp. 173-182 (1986).
Coleman et al., Pharm. Pharmacolo. vol. 37, pp. 878-883 (1985).
Diamond et al., Current Therapeutic Research, vol. 7(3), pp. 170-175 (1965).
Elsager, Edward, Human Antiparasitic Agents, Chapter 14a, Ann. Rep. Med. Chem, pp. 136-149, (1965).
Florence et al., “Effect of formulation of intramuscular injections of phenothiazines on duration of activity”, Journal of Pharmaceutical Sciences, vol. 65(11), pp. 1665-1668, (1976).
Goldberg et al., “A double-blind study of tofrani pamoate vs. tofrani hydrochloride”, Psychosomatics, vol. XIII, pp. 131-134 (Mar.-Apr. 1972).
Gould, “Salt Selection for basic drugs”, Int. Journal of Pharmceuticals, vol. 33, pp. 201-217 (1986).
Injectable Product-Fundamentals, Preparation of Drug and Application, 1st edition, pp. 20-21 (1995).
Khorana, Indian Journal of Physiology and Pharmacology, vol. 25(4), pp. 331-338 (1989).
Miller et al., “A controlled study of single-dose administration of imipramine pamoate in endogenous depression”, Current Therapeutic Research, vol. 15, No. 9. 10, (Oct. 1973).
Saias et al., English translation, “A class of oral retard and sustained effort drugs: the pamoates”, Annales Pharmaceutiques francaises, vol. 27 (9-10), pp. 557-570 (1969).
Saias et al., French version, “A class of oral retard and sustained effort drugs: the pamoates”, Annales Pharmaceutiques francaises, vol. 27 (9-10), pp. 557-570 (1969).
Sustained and Controlled Release Drug Delivery Systems, edited by Robinson, passim (pp. 4, 5, 47, 48, 136, 137, 175, 358-360, 412-415, 462) (1978).
Thompson et al., “Laboratory studies on 4,6,-diamino-1-(p-chlorophenyl)-1,2-dihydro-2,2-dimethyl-s-triazine pamoate (CI-501) as a repository antimalarial drug”, Research Div., Parke, Davis & Company, Ann Arbor, MI, pp. 481-493, 1965.
Affidavit of Expert Dr. Arvind Kumar Bansal filed in Indian Opposition relating to Indian Patent No. 220287 (Eli Lilly), Nov. 26, 2009.
PCT/US98/20426 International Search Report Jan. 12, 1999.
PCT/US99/06417International Search Report Jul. 27, 1999.
Felberbaum, “Treatment of uterine fibroids with a slow release formulation of the gonadotrophin releasing hormone antagonist Cetrorelix”, Hum Reprod vol. 13(6), pp. 1660-1668, (1998).
Randell et al., “Prolonged Analgesia after Epidural Injection of a Poorly Soluble Salt of Fentanyl”, Anesth Analg. vol. 79, pp. 905-910 (1994).
Silverman et al., “A case of Accidental Parenteral Injection of Povan”, Toxicology and Applied Pharmacology vol. 16 (3), pp. 740-742 (May 1970).
Wells, Pharmaceutical Preformulation: The Physiochemical Properties of Drug Substances, ISBN 0-7458-0276-1, Section 2.3, pp. 28-40 (1998).
Chile search results from Application No. 585-99, Mar. 29, 1999.
Chile written answering opposition and English translation, Application No. 585-99, Sep. 2000.
Colombia Opposition filed against application No. 99-018,903 (Spanish with English translation), Aug. 2001.
Colombia Response to Opposition 99-018,903 (Spanish with English translation).pdf, Aug. 2002.
Ecuador Oppostion SP 94-1212 (Spanish with English translation), Jan. 2000.
Ecuador Response to Opposition SP 99-2901 (Spanish with English translation).pdf, Dec. 1999.
Ecuador Search Report SP 99-2901 2004.
European Search Report EP99915009.pdf, Oct. 26, 2001.
European Supplemental Partial European Search Report from EP 98949632 Apr. 19, 2006.
Hungarian Search Report for HU P0004534 Oct. 29, 2002.
Hungarian Search Report for HU P0103636 Apr. 17, 2003.
Indian Notice of Opposition re Patent 220287, May 2009.
Indian Notice of Opposition re Patent 220287, Johnson Affidavit, Aug. 2009.
Indian Notice of Opposition re Patent 220287, Mitchell Affidavit, Aug. 2009.
Opposition re IN Patent No. 220287, Reply Evidence by Opponent and index, Sep. 2009.
Japanese official action in JP 2000-513467 Jun. 2, 2009 with associate letter.
Exhibit 11, book entitled “Novel Drug Delivery Systems”, Chapter 8, 1992.
Exhibit 14, “Salt Forms of Drugs and Adsorption”, Encyclopedia of Pharmaceutical Technology vol. 13, Marcel Dekker, Inc. (1995).
Exhibit 15, Psychopharmacologic drugs Advisory Committee Briefing document for Zyprexa Olanzapine Pamoate (OP) report that was submitted to the US FDA by Lilly, Feb. 2008.
Exhibit 16, summary product characteristics of ZypAdhera (Olanzapine Pamoate long action injection) available at EMEA website, Feb. 2008.
Exhibit 17, article entitled “Upcoming agents for the treatment of schizophrenia, mechansim of action, efficacy and tolerability” published in Drugs vol. 68 (16): pp. 2269-2292 (2008).
Notice of Intent to Issue Ex Parte Reexamination Certificate, May 24, 2010, U.S. Appl. No. 90/010,584.
Coleman Brenda L
Ebersole Ted Joseph
Eli Lilly and Company
Lentz Nelsen L.
LandOfFree
Olanzapine pamoate dihydrate does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Olanzapine pamoate dihydrate, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Olanzapine pamoate dihydrate will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2650824